Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology firm, will present at the Credit Suisse 31st Annual Healthcare Conference from November 7-10, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology firm, will present at the Credit Suisse 31st Annual Healthcare Conference from November 7-10, 2022. Their presentation is scheduled for November 8, 2022, at 8:00 AM PT and will be accessible via a webcast on their website. The replay will be available for 30 days post-event. Magenta focuses on developing innovative medicines aimed at expanding the curative potential of stem cell transplants for patients with blood cancers, genetic disorders, and autoimmune diseases.
Details
News Market Reaction – MGTA
The recorded move for MGTA in the trading session of this news was -3.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that the company will present at the Credit Suisse 31st Annual Healthcare Conference being held November 7-10, 2022.
The webcast of Magenta's presentation will be accessible at 8:00am Pacific Time on Tuesday, November 8, 2022 on the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations. The replay will be available for 30 days following the event.
About Magenta Therapeutics
Magenta Therapeutics is a clinical-stage biotechnology company developing medicines designed to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise to revolutionize immune and blood reset to allow more patients to take advantage of the curative potential of stem cell transplant as well as potentially improve eligibility for future gene therapies.
Magenta is based in Cambridge, Mass. For more information, please visit www.magentatx.com.
Contact:
Jill Bertotti, Real Chemistry (advisor to Magenta)
714-225-6726
jbertotti@realchemistry.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.